Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Basal Insulin

Mylan Wins Final Patent Dispute vs. Sanofi; Biocon Bs-glargine Final FDA Approval Imminent

Here is a brief preview of this blast: Mylan announced the US Patent and Trademark Appeal Board (PTAB) ruled in Mylan's favor during recent inter partes review (IPR) proceedings. Importantly, Mylan's outgoing CEO, Heather Bresch, commented, "...with this final victory in hand, we now look forward to working with FDA to complete the regulatory review process and introduce Semglee in the U.S. as soon as possible." Recall, Mylan/Biocon has disclosed that the FDA action date for their bs-glargine is sometime in June 2020. Below, FENIX provides a brief overview of the PTAB ruling as well as thoughts on the impending approval and launch of the Mylan/Biocon bs-glargine product.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.